Author is bullish Regenxbio after a strong JPM Healthcare conference call, citing H1 2026 milestones including a first PDUFA, first dose in DR phllb/lll, and pivotal DMD data.
RGNX — LONG The author reports a great JPM Healthcare conference call for Regenxbio and points to several H1 2026 milestones: a first PDUFA, first dose in DR phllb/lll, and pivotal data for DMD. They expect it to be a great year and recommend due diligence. No specific risk is stated.
Looking forward to H1 26 with several milestones coming. 1st pdufa, 1st dose in DR phllb/lll, and pivotal data for DMD.
This Reddit post, published January 14, 2026, features u/fbksminer discussing RGNX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/fbksminer · Tickers: RGNX